Microfluidic-based direct identification of virus-neutralizing antibodies from comprehensive B-cell repertoires of elite controllers of infection (##DIVA#) for a rapid anti-pandemic response

• Forschungsstelle: INNOSUISSE
• Projektnummer: 46963.1 IP-LS
• Projekttitel Englisch: Microfluidic-based direct identification of virus-neutralizing antibodies from comprehensive B-cell repertoires of elite controllers of infection (##DIVA#) for a rapid anti-pandemic response

Kurzbeschreibung (Deutsch)

Microfluidic-based direct identification of virus-neutralizing antibodies from comprehensive B-cell repertoires of elite controllers of infection (##DIVA#) for a rapid anti-pandemic response

Kurzbeschreibung (Englisch)

Microfluidic-based direct identification of virus-neutralizing antibodies from comprehensive B-cell repertoires of elite controllers of infection (##DIVA#) for a rapid anti-pandemic response

Abstract (Deutsch)

The innovative microfluidic screening platform #DIVA will allow direct discovery of neutralizing antibodies against viral infections and thus shorten the drug development process. It will be benchmarked with the current pandemic SARS-CoV-2 and applied to the discovery of CMV-neutralizing antibodies.